Aggregated measures within each VD category
| Seroconversion | Total | VD category | ||||
| 1 | 2 | 3 | 4 | |||
| Severe deficiency | Deficiency | Insufficiency | Sufficiency | |||
| 1 | Study count | 208 | 44 | 45 | 80 | 39 |
| Median VD (nmol/L) | 54.2 (34.3–68.6) | 20.5 (15.6–25.7) | 41.4 (37.8–45.5) | 60.4 (55.8–66.5) | 84.3 (78.2–94.8) | |
| Median Age (years) | 42.0 (31.0–50.0) | 40.5 (31.0–47.5) | 38.0 (30.0–48.5) | 43.0 (30.5–50.0) | 43.0 (31.0–53.0) | |
| Age count (%) | ||||||
| Age <50 (years) | 152 (73.1%) | 35 (79.5%) | 34 (75.6%) | 58 (72.5%) | 25 (64.1%) | |
| Age ≥50 (years) | 56 (26.9%) | 9 (20.5%) | 11 (24.4%) | 22 (27.5%) | 14 (35.9%) | |
| Sex count (%) | ||||||
| Male | 53 (25.5%) | 18 (40.9%) | 12 (26.7%) | 18 (22.5%) | 5 (12.8%) | |
| Female | 155 (74.5%) | 26 (59.1%) | 33 (73.3%) | 62 (77.5%) | 34 (87.2%) | |
| Median BMI (kg/m²) | 26.3 (23.1–30.1) | 27.0 (23.5–30.5) | 26.0 (23.5–32.0) | 26.0 (23.0–38.5) | 26.0 (23.0–29.0) | |
| BMI count (%) | ||||||
| BMI <30 (kg/m²) | 156 (75.0%) | 32 (72.7%) | 30 (66.7%) | 62 (77.5%) | 32 (82.1%) | |
| BMI ≥30 (kg/m²) | 52 (25.0%) | 12 (27.3%) | 15 (33.3%) | 18 (22.5%) | 7 (17.9%) | |
| Ethnicity count (%) | ||||||
| BAME | 69 (33.2%) | 33 (75.0%) | 11 (24.4%) | 13 (16.3%) | 12 (30.8%) | |
| White | 139 (66.8%) | 11 (25.0%) | 34 (75.6%) | 67 (83.7%) | 27 (69.2%) | |
| Comorbidity count (%) | ||||||
| 1+ comorbidities | 74 (35.6%) | 15 (34.1%) | 12 (26.7%) | 30 (37.5%) | 17 (43.6%) | |
| 0 comorbidities | 134 (64.4%) | 29 (65.9%) | 33 (73.3%) | 50 (62.5%) | 22 (56.4%) | |
| 0 | Study count | 171 | 16 | 53 | 71 | 31 |
| Median VD (nmol/L) | 57 (41.3–68.8) | 24.6 (17.0–26.3) | 41.3 (36.7–45.3) | 61.2 (57.1–66.6) | 85.4 (77.7–98.6) | |
| Median age (years) | 40.0 (30.0–50.0) | 30.0 (26.5–46.5) | 33.0 (27.0–47.5) | 42.0 (31.0–53.0) | 48.0 (39.0–56.0) | |
| Age count (%) | ||||||
| Age <50 (years) | 122 (71.3%) | 12 (75.0%) | 43 (81.1%) | 48 (67.6%) | 19 (61.3%) | |
| Age ≥50 (years) | 49 (28.7%) | 4 (25.0%) | 10 (18.9%) | 23 (32.4%) | 12 (38.7%) | |
| Sex count (%) | ||||||
| Male | 44 (25.7%) | 3 (18.8%) | 15 (28.3%) | 17 (23.9%) | 9 (29.0%) | |
| Female | 127 (74.3%) | 13 (81.2%) | 38 (71.7%) | 54 (76.1%) | 22 (71.0%) | |
| Median BMI (kg/m²) | 25.6 (22.7–30.2) | 24.0 (22.0–30.5) | 26.0 (22.0–33.0) | 27.0 (23.0–30.0) | 24.0 (22.0–26.0) | |
| BMI count (%) | ||||||
| BMI <30 (kg/m²) | 128 (74.9%) | 12 (75.0%) | 35 (66.0%) | 53 (74.6%) | 28 (90.3%) | |
| BMI ≥30 (kg/m²) | 43 (25.1%) | 4 (25.0%) | 18 (34.0%) | 18 (25.4%) | 3 (9.7%) | |
| Ethnicity count (%) | ||||||
| BAME | 36 (21.1%) | 9 (56.2%) | 9 (17.0%) | 13 (18.3%) | 5 (16.1%) | |
| White | 135 (78.9%) | 7 (43.8%) | 44 (83.0%) | 58 (81.7%) | 26 (83.9%) | |
| Comorbidity count (%) | ||||||
| 1+ comorbidities | 72 (42.1%) | 6 (37.5%) | 15 (28.3%) | 38 (53.5%) | 13 (41.9%) | |
| 0 comorbidities | 99 (57.9%) | 10 (62.5%) | 38 (71.7%) | 33 (46.5%) | 18 (58.1%) | |
| Total population | Study count | 379 | 60 | 98 | 151 | 70 |
| Median VD (nmol/L) | 55.4 (39.2–68.8) | 22.1 (15.7–26.0) | 41.4 (37.3–45.3) | 61.0 (56.3–66.5) | 85.1 (78.2–95.8) | |
| Median age (years) | 42.0 (30.0–50.0) | 35.5 (28.5–47.5) | 35.5 (28.0–47.0) | 43.0 (31.0–51.0) | 46.5 (35.0–54.0) | |
| Age count (%) | ||||||
| Age <50 (years) | 274 (72.3%) | 47 (78.3%) | 77 (78.6%) | 106 (70.2%) | 44 (62.9%) | |
| Age ≥50 (years) | 105 (27.7%) | 13 (21.7%) | 21 (21.4%) | 45 (29.8%) | 26 (37.1%) | |
| Sex count (%) | ||||||
| Male | 97 (25.6%) | 21 (35.0%) | 27 (27.6%) | 35 (23.2%) | 14 (20.0%) | |
| Female | 282 (74.4%) | 39 (65.0%) | 71 (72.4%) | 116 (76.8%) | 56 (80.0%) | |
| Median BMI (kg/m²) | 25.9 (22.9–30.1) | 25.5 (23.0–30.5) | 26.0 (23.0–33.0) | 26.0 (23.0–29.0) | 25.0 (23.0–28.0) | |
| BMI count (%) | ||||||
| BMI <30 (kg/m²) | 284 (74.9%) | 44 (73.3%) | 65 (66.3%) | 115 (76.2%) | 60 (85.7%) | |
| BMI ≥30 (kg/m²) | 95 (25.1%) | 16 (26.7%) | 33 (33.7%) | 36 (23.8%) | 10 (14.3%) | |
| Ethnicity count (%) | ||||||
| BAME | 105 (27.7%) | 42 (70.0%) | 20 (20.4%) | 26 (17.2%) | 17 (24.3%) | |
| White | 274 (72.3%) | 18 (30.0%) | 78 (79.6%) | 125 (82.8%) | 53 (75.7%) | |
| Comorbidity count (%) | ||||||
| 1+ comorbidities | 146 (38.5%) | 21 (35.0%) | 27 (27.6%) | 68 (45.0%) | 30 (42.9%) | |
| 0 Comorbidities | 233 (71.5%) | 39 (65.0%) | 71 (72.4%) | 83 (55.0%) | 40 (57.1%) | |
Comparisons were initially grouped by their seroconversion status. Continuous variables are presented as median (IQR). Categorical data were presented as count (%).
BAME, black, Asian and minority ethnic; BMI, body mass index; VD, vitamin D.